Cash-flushed Moderna searches for its next home-run drug

Behind on your booster shots? We won’t judge, but we can’t say the same for vaccine makers who feel the pressure of lower demand. Up to 70% of Americans are behind on their vaccine shots. Global vaccine demand has fallen off a cliff… Global demand for vaccines has been down by over half since the…

Read more

CRISPR stocks make progress as the gene-editing technique turns 10

Over the past two days, we looked at the state of the biotech industry (Pt.1) and talked about ways to invest in biotech using ETFs (Pt.2). Today, we finish off the series by saying happy belated 10th birthday to CRISPR… sorry, who? Nearly ten years ago, researchers made a breakthrough that changed the course of…

Read more

How to invest in biotech stocks without being an expert: Biotech ETFs

In part one yesterday, we covered the biotech industry and the early signs of a bottom in the industry. Like most of us who last took a science course in high school, you’re probably no expert on the subject. So what can you do if you’re looking for exposure without grinding out a Ph.D.? The…

Read more

Rise in biotech mergers and acquisitions point to a bottom in the industry

The biotech industry has staged a heavy rebound in the past month, with the iShares Biotechnology ETF (NASDAQ:IBB) rising 17%. One of the biggest drivers of value in the biotech industry is slowly coming back to life… The biotech way of life Mergers and acquisitions (M&A) are a big part of the biotech/pharmaceutical industry. 1/…

Read more

Biotech stocks bounce on Wall Street optimism

The biotech industry is showing signs of life after a months-long struggle. Except this time, investors are holding companies to a higher standard. No more disappointment, please The past year has been described as “the most extreme period of stress in the modern history of biotech” — as miserable market conditions, diminishing investor interest, and…

Read more

Moderna gets added to the S&P 500 — where does its stock go from here?

Vaccine maker Moderna officially joined the famous S&P 500 — the big leagues for big companies. But what comes next? What’s the big deal? Last year, investors were unsure which vaccine would take the lead or how profitable they would be. After the US gave its emergency vaccine authorizations, Pfizer and Moderna became clear winners….

Read more